Filing Analysis
Cocrystal Pharma announced that its oral protease inhibitor, CDI-988, was featured in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026). The presentation focused on the drug's mechanism of action and its current clinical advancement.
Key Facts
- Oral presentation at ICAR 2026 in Prague, Czech Republic on April 30, 2026.
- Featured drug candidate: CDI-988, an oral protease inhibitor.
- Presentation covered mechanism of action and clinical progress.
Cocrystal Pharma announced that the FDA has granted Fast Track designation to its oral antiviral candidate, CDI-988, for the treatment and prophylaxis of norovirus infection. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill unmet medical needs.
Key Facts
- FDA granted Fast Track designation to CDI-988 on April 2, 2026.
- CDI-988 is an oral, direct-acting protease inhibitor candidate.
- The drug is being developed for both treatment and prophylaxis of norovirus infection.
- The company claims CDI-988 is the first oral antiviral candidate for this specific indication.
Cocrystal Pharma, Inc. (COCP) filed an 8-K to announce its financial results for the fiscal year ended December 31, 2025. The filing includes a press release with business updates and financial performance metrics.
Red Flags
- Clerical inconsistency: The body text of Item 2.02 incorrectly states the press release was issued on November 14, 2025, for the fiscal year ended December 31, 2025, which is chronologically impossible.
Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The press release (Exhibit 99.1) is dated March 31, 2026.
- The report was signed by James Martin, who holds the dual role of Co-Chief Executive Officer and Chief Financial Officer.
- The filing includes a clerical error in the Item 2.02 text, which incorrectly references a November 14, 2025 date for the year-end results announcement.
Cocrystal Pharma, Inc. reported the passing of Dr. Anthony Japour, a member of the company's Board of Directors, on March 10, 2026.
Key Facts
- The company was notified of Dr. Anthony Japour's death on March 10, 2026.
- Dr. Japour served as a member of the Board of Directors.
- The filing was made under Item 5.02 of Form 8-K.
Cocrystal Pharma, Inc. issued a press release on March 9, 2026, providing a clinical update on its Phase 1b norovirus challenge study. The study is evaluating the drug candidate CDI-988 for its efficacy as both a preventive and treatment for norovirus infections.
Key Facts
- The filing was made under Item 7.01 Regulation FD Disclosure on March 9, 2026.
- The update concerns the Phase 1b norovirus challenge study for drug candidate CDI-988.
- CDI-988 is being developed as both a preventive and a treatment for norovirus.
- The report was signed by James Martin, who serves as both Co-Chief Executive Officer and Chief Financial Officer.
Cocrystal Pharma disclosed via Regulation FD that its oral norovirus protease inhibitor CDI-988 will be featured at the International Society for Antiviral Research Conference (ICAR) 2026 in Prague, April 27–May 1, 2026. This is a routine scientific conference presentation announcement with no material financial or structural changes to the company.
Red Flags
- James Martin holds dual role as Co-CEO and CFO, concentrating executive authority
- Reg FD disclosure is 'furnished' not 'filed,' offering limited investor protection
Key Facts
- CDI-988 is described as the Company's 'first oral norovirus protease inhibitor'
- Drug candidate will be featured at ICAR 2026, held April 27–May 1, 2026 in Prague, Czech Republic
- Filing signed by James Martin, Co-Chief Executive Officer and Chief Financial Officer (dual role)
- Company is incorporated in Delaware, headquartered in Bothell, WA
- Trades on Nasdaq Capital Market under ticker COCP
- Information furnished under Item 7.01 (not 'filed'), limiting liability exposure